Relationships of Serum CTRP3 with Diabetic Nephropathy Associated Metabolic Parameters and Its Diagnostic Value

doi:10.12114/j.issn.1007-9572.2020.00.323

Abstract

Abstract: Background　Diabetic nephropathy（DN）is one of the serious complications of type 2 diabetes mellitus（T2DM）.Previous studies have suggested that C1q/TNF-related protein-3（CTRP3）may play a role in the development of DN.However，the relationship between CTRP3 and DN remains unclear.Objective　To investigate the relationships of serum CTRP3 with DN and associated metabolic parameters.Methods　Fifty-four patients with T2DM（T2DM group），55 with type 2 diabetic nephropathy（DN group） from Binzhou Medical University Hospital，and 55 healthy people （control group） were enrolled from July 2017 to June 2018.The three groups were tested for metabolic parameters.Moreover，ELISA was adopted to detect the concentrations of CTRP3，interleukin 6（IL-6），tumor necrosis factor-α（TNF-α），and adiponectin（APN）.Pearson correlation test was used for correlation analysis.Multiple linear regression was used to analyze the influencing factors of CTRP3 in each group.And receiver operating characteristic curve （ROC）was plotted to analyze the ability of CTRP3 in distinguishing disease status.And receiver operating characteristic curve （ROC）was plotted to analyze the ability of CTRP3 in distinguishing DN and T2DM.Results　Compared with the control group，serum IL-6 and TNF-α were significantly increased in T2DM and DN groups，whereas APN and CTRP3 levels were notably decreased（P<0.05）.DN group showed higher average IL-6 level but lower average CTRP3 levels than T2DM group（P<0.05）.Female and overweight/obesity were associated with higher serum CTRP3 level（P<0.05）.Multiple Logistic regression analysis results showed that CTRP3 was independently associated with the risks of T2DM 〔OR=0.804，95%CI（0.731，0.883），P<0.001〕 and DN 〔OR=0.730，95%CI（0.654，0.814），P<0.001〕.Pearson correlation analysis showed that in the control group，CTRP3 was negatively correlated with insulin（r=-0.415）and insulin resistance index（HOMA-IR）（r=-0.438）（P<0.05）.CTRP3 was negatively correlated with insulin，HOMA-IR，HbA1c，IL-6 and TNF-α in T2DM group （r=-0.312，-0.327，-0.286，-0.342，-0.359） and in DN group（r=-0.407，-0.436，-0.287，-0.386，-0.365）（P<0.05）.CTRP3 also showed a negative correlation with Cr（r=-0.389）in DN group（P<0.05）.Moreover，it was positively correlated with eGFR and APN in T2DM group（r=0.274，0.436） and in DN group（r=0.428，0.273）（P<0.05）.Besides，multiple linear regression analysis indicated that HOMA-IR
〔β=-64.330，95%CI（-92.067，-9.537）〕 and APN 〔β=9.210，95%CI（4.510，16.627）〕 were independently associated with CTRP3 in T2DM group（P<0.05）.And HOMA-IR 〔β=-62.773，95%CI（-122.250，-13.348）〕and eGFR 〔β=0.953，95%CI（0.327，2.442）〕were independently associated with CTRP3 in DN group（P<0.05）.The AUC for CTRP3 in the diagnosis of DN was 0.881〔95%CI（0.820，0.943）〕，the sensitivity was 76.36%，and the specificity was 90.91%.Conclusion　CTRP3 was significantly reduced in patients with T2DM and DN，and was independently associated with the risks of T2DM and DN，and showed high sensitivity and specificity in the diagnosis of DN，indicating that it may play a role in the pathogenesis of DN and may be used as a potential biomarker for DN.

Key words: Diabetic nephropathies, Type 2 diabetes, C1q/TNF-related protein-3, Adipokines, Inflammation, Diagnosis

摘要： 背景　糖尿病肾病（DN）是2型糖尿病（T2DM）严重并发症之一，一些证据表明补体C1q/肿瘤坏死因子相关蛋白3（CTRP3）可能在DN中发挥作用，但目前关于CTRP3与DN的关系尚不明确。目的　探讨血清CTRP3水平对DN及其代谢参数的影响。方法　选取2017年7月—2018年6月滨州医学院附属医院收治的T2DM患者54例（T2DM组），2型糖尿病肾病患者55例（DN组），并选取55例正常健康体检者作为对照组，三组均进行代谢参数检测，并采用酶联免疫吸附测定法（ELISA）检测CTRP3、白介素6（IL-6）、肿瘤坏死因子-α（TNF-α）、脂联素（APN）水平，比较三组间的差异。采用Pearson相关性分析进行相关性检验，多重线性回归分析探讨各组CTRP3的影响因素，受试者工作特征（ROC）曲线评估CTRP3对DN的诊断价值。结果　T2DM组、DN组IL-6、TNF-α水平高于对照组，DN组IL-6水平高于T2DM组（P<0.05）；T2DM组、DN组APN、CTRP3水平低于对照组，DN组CTRP3水平低于T2DM组（P<0.05）；女性CTRP3水平高于男性，正常体质量者CTRP3水平高于超重/肥胖者（P<0.05）。多项逻辑回归分析结果显示，CTRP3水平与T2DM〔OR=0.804，95%CI（0.731，0.883），P<0.001〕和DN〔OR=0.730，95%CI（0.654，0.814），P<0.001〕的风险之间存在着独立的相关性。Pearson相关性分析结果显示，在对照组中，CTRP3与胰岛素（r=-0.415）、胰岛素抵抗指数（HOMA-IR）（r=-0.438）呈负相关（P<0.05）；在T2DM组和DN组中，CTRP3与胰岛素（r=-0.312、-0.407）、HOMA-IR（r=-0.327、-0.436）、糖化血红蛋白（HbA1c）（r=-0.286、-0.287）、IL-6（r=-0.342、-0.386）和TNF-α（r=-0.359、-0.365）呈负相关，但与肾小球滤过率（eGFR）（r=0.274、0.428）、APN（r=0.436、0.273）呈正相关（P<0.05）；在DN组中，CTRP3与肌酐（Cr）（r=-0.389）呈负相关（P<0.05）。多元线性回归分析结果显示，T2DM组中HOMA-IR〔β=-64.330，95%CI（-92.067，-9.537）〕、APN〔β=9.210，95%CI（4.510，16.627）〕，DN组的HOMA-IR〔β=-62.773，95%CI（-122.250，-13.348）〕、eGFR〔β=0.953，95%CI（0.327，2.442）〕是CTRP3的影响因素（P<0.05）。CTRP3诊断DN的ROC曲线下面积（AUC）为0.881〔95%CI（0.820，0.943）〕，灵敏度为76.36%，特异度为90.91%。结论　CTRP3在T2DM和DN患者中明显降低，并与T2DM和DN的风险之间存在着独立的相关性。CTRP3诊断DN具有较高的灵敏度与特异度，在DN的发病机制中具有一定的作用，可作为DN的潜在生物标志物。

关键词: 糖尿病肾病, 2型糖尿病, 补体C1q/肿瘤坏死因子相关蛋白3, 脂肪因子, 炎症, 诊断

AN Chao,LU Yanmin,ZHANG Ying, et al. Relationships of Serum CTRP3 with Diabetic Nephropathy Associated Metabolic Parameters and Its Diagnostic Value 　[J]. Chinese General Practice, 2020, 23(26): 3303-3310. DOI: 10.12114/j.issn.1007-9572.2020.00.323.
安超,卢艳敏,张颖等. 血清补体C1q/肿瘤坏死因子相关蛋白3水平对糖尿病肾病代谢参数的影响及其诊断价值研究[J]. 中国全科医学, 2020, 23(26): 3303-3310. DOI: 10.12114/j.issn.1007-9572.2020.00.323.

References

［1］SERAFINCEANU C，NECULAESCU C，CIMPONERIU D，et al．Impact of gender and dialysis modality on early mortality risk in diabetic ESRD patients：data from a large single center cohort［J］．Int Urol Nephrol，2014，46（3）：607-614．DOI：10.1007/s11255-013-0589-6.
［2］OUCHI N，PARKER J L，LUGUS J J，et al．Adipokines in inflammation and metabolic disease［J］．Nat Rev Immunol，2011，11（2）：85-97．DOI：10.1038/nri2921.
［3］PIYA M K，MCTERNAN P G，KUMAR S.Adipokine inflammation and insulin resistance：the role of glucose，lipids and endotoxin［J］．J Endocrinol，2013，216（1）：T1-15．DOI：10.1530/JOE-12-0498.
［4］MATSUDA M，SHIMOMURA I.Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases［J］．Rev Endocr Metab Disord，2014，15（1）：1-10．DOI：10.1007/s11154-013-9271-7.
［5］PANDURU N M，SARAHEIMO M，FORSBLOM C，et al．Urinary adiponectin is an independent predictor of progression to end-stage renal disease in patients with type 1 diabetes and diabetic nephropathy［J］．Diabetes Care，2015，38（5）：883-890．DOI：10.2337/dc14-2276.
［6］LI Y，WRIGHT G L，PETERSON J M.C1q/TNF-related protein 3（CTRP3）function and regulation［J］．Compr Physiol，2017，7（3）：863-878．DOI：10.1002/cphy.c160044.
［7］YI W，SUN Y，YUAN Y X，et al．C1q/tumor necrosis factor-related protein-3，a newly identified adipokine，is a novel antiapoptotic，proangiogenic，and cardioprotective molecule in the ischemic mouse heart［J］．Circulation，2012，125（25）：3159-3169．DOI：10.1161/CIRCULATIONAHA.112.099937.
［8］ZHANG J X，ZHANG B L，CHENG Y Y，et al．Low serum CTRP3 levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus［J］．Cytokine，2018，106：131-135．DOI：10.1016/j.cyto.2017.10.023.
［9］贺晓雯，徐玉祥，张九芝，等．糖尿病肾病CKD-Ⅴ期患者血清CTRP3、CTRP9变化与血管钙化的关系［J］．现代医学，2019，47（9）：1075-1080.
HE X W，XU Y X，ZHANG J Z，et al．Relationship between changes of serum CTRP3，CTRP9 and vascular calcification in chronic kidney disease stage 5 patients with diabetic nephropathy［J］．Modern Medical Journal，2019，47（9）：1075-1080.
［10］中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）［J］．中华糖尿病杂志，2018，10（1）：4-67．DOI：10.3760/cma.j.issn.1674-5809.2018.01.003.http：//www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhtnb201801003.
［11］LI X，JIANG L，YANG M，et al．GLP-1 receptor agonist increases the expression of CTRP3，a novel adipokine，in 3T3-L1 adipocytes through PKA signal pathway［J］．J Endocrinol Invest，2015，38（1）：73-79．DOI：10.1007/s40618-014-0156-8.
［12］SCH?FFLER A，EHLING A，NEUMANN E，et al．Role of specificity protein-1，PPARgamma，and pituitary protein transcription factor-1 in transcriptional regulation of the murine CORS-26 promoter［J］．Biochim Biophys Acta，2004，1678（2/3）：150-156．DOI：10.1016/j.bbaexp.2004.02.006.
［13］LEVEY A S，CORESH J，GREENE T，et al．Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values［J］．Clin Chem，2007，53（4）：766-772．DOI：10.1373/clinchem.2006.077180.
［14］姚丽君，吴文君，蒋艳敏，等．血清颗粒蛋白前体与糖尿病及其微血管并发症的关系［J］．国际内分泌代谢杂志，2018，38（1）：44-47．DOI：10.3760/cma.j.issn.1673-4157.2018.01.012.
YAO L J，WU W J，JIANG Y M，et al．Relationship between progranulin，diabetes and its microvasular complications［J］．International Journal of Endocrinology and Metabolism，2018，38（1）：44-47．DOI：10.3760/cma.j.issn.1673-4157.2018.01.012.
［15］ZIEMKE F，MANTZOROS C S.Adiponectin in insulin resistance：lessons from translational research［J］．Am J Clin Nutr，2010，91（1）：258S-261．DOI：10.3945/ajcn.2009.28449C.
［16］FADAEI R，MORADI N，BARATCHIAN M，et al．Association of C1q/TNF-related protein-3（CTRP3）and CTRP13 serum levels with coronary artery disease in subjects with and without type 2 diabetes mellitus［J］．PLoS One，2016，11（12）：e0168773．DOI：10.1371/journal.pone.0168773.
［17］FADAEI R，MORADI N，KAZEMI T，et al．Decreased serum levels of CTRP12/adipolin in patients with coronary artery disease in relation to inflammatory cytokines and insulin resistance［J］．Cytokine，2019，113：326-331．DOI：10.1016/j.cyto.2018.09.019.
［18］SHANAKI M，MORADI N，FADAEI R，et al．Lower circulating levels of CTRP12 and CTRP13 in polycystic ovarian syndrome：Irrespective of obesity［J］．PLoS One，2018，13（12）：e0208059．DOI：10.1371/journal.pone.0208059.
［14］IWANE T，MARUYAMA M，MATSUKI M，et al．Management of intractable pain in adiposis dolorosa with intravenous administration of lidocaine［J］．Anesth Analg，1976，55（2）：257-259．DOI：10.1213/00000539-197603000-00028.
［15］BOAS R A，COVINO B G，SHAHNARIAN A.Analgesic responses to i.v.lignocaine［J］．Br J Anaesth，1982，54（5）：501-505．DOI：10.1093/bja/54.5.501.
［16］PETERSEN P，KASTRUP J，ZEEBERG I，et al．Chronic pain treatment with intravenous lidocaine［J］．Neurol Res，1986，8（3）：189-190．DOI：10.1080/01616412.1986.11739753.
［17］KURABE M，FURUE H，KOHNO T.Intravenous administration of lidocaine directly Acts on spinal dorsal horn and produces analgesic effect：an in vivo patch-clamp analysis［J］．Sci Rep，2016，6：26253．DOI：10.1038/srep26253.
［18］TREMONT-LUKATS I W，HUTSON P R，BACKONJA M M.A randomized，double-masked，placebo-controlled pilot trial of extended Ⅳ lidocaine infusion for relief of ongoing neuropathic pain［J］．Clin J Pain，2006，22（3）：266-271．DOI：10.1097/01.ajp.0000169673.57062.40.
［19］VIOLA V，NEWNHAM H H，SIMPSON R W.Treatment of intractable painful diabetic neuropathy with intravenous lignocaine［J］．J Diabetes Complicat，2006，20（1）：34-39．DOI：10.1016/j.jdiacomp.2005.05.007.
［20］罗兴均，简道林.静脉利多卡因在疼痛治疗中的应用研究［J］．实用医学杂志，2011，27（13）：2477-2479.
LUO X J，JIAN D L.Application of intravenous lidocaine in the treatment of pain［J］．The Journal of Practical Medicine，2011，27（13）：2477-2479.
［21］DUNN L K，DURIEUX M E.Perioperative use of intravenous lidocaine［J］．Anesthesiology，2017，126（4）：729-737．DOI：10.1097/ALN.0000000000001527.
［22］DETOLEDO J C.Lidocaine and seizures［J］．Ther Drug Monit，2000，22（3）：320-322．DOI：10.1097/00007691-200006000-00014.
［23］WEINBERG L.Pharmacokinetics and pharmacodynamics of lignocaine：a review［J］．World J Anesthesiol，2015，4（2）：17．DOI：10.5313/wja.v4.i2.17.
［24］ABELSON K S，H?GLUND A U.Intravenously administered lidocaine in therapeutic doses increases the intraspinal release of acetylcholine in rats［J］．Neurosci Lett，2002，317（2）：93-96．DOI：10.1016/s0304-3940（01）02440-5.
［25］CARABALONA J F，DELWARDE B，DUCLOS A，et al．Serum concentrations of lidocaine during bariatric surgery［J］．Anesth Analg，2018．DOI：10.1213/ANE.0000000000003905.
［26］周莹，朱涛，刘进.单次静脉注射利多卡因血药浓度的测定［J］．遵义医学院学报，2014，37（2）：208-211．DOI：10.14169/j.cnki.zunyixuebao.2014.02.018.
ZHOU Y，ZHU T，LIU J.Detection of plasma concentrations of single intravenous lidocaine［J］．Journal of Zunyi Medical University，2014，37（2）：208-211．DOI：10.14169/j.cnki.zunyixuebao.2014.02.018.
［27］DE OLIVEIRA C M，ISSY A M，SAKATA R K.Intraoperative intravenous lidocaine［J］．Rev Bras Anestesiol，2010，60（3）：325-333．DOI：10.1016/S0034-7094（10）70041-6.
［19］WAGNER R M，SIVAGNANAM K，CLARK W A，et al．Divergent relationship of circulating CTRP3 levels between obesity and gender：a cross-sectional study［J］．Peer J，2016，4：e2573．DOI：10.7717/peerj.2573.
［20］YAN Z Y，ZHAO J L，GAN L，et al．CTRP3 is a novel biomarker for diabetic retinopathy and inhibits HGHL-induced VCAM-1 expression in an AMPK-dependent manner［J］．PLoS One，2017，12（6）：e0178253．DOI：10.1371/journal.pone.0178253.
［21］BAN B，BAI B，ZHANG M M，et al．Low serum cartonectin/CTRP3 concentrations in newly diagnosed type 2 diabetes mellitus：in vivo regulation of cartonectin by glucose［J］．PLoS One，2014，9（11）：e112931．DOI：10.1371/journal.pone.0112931.
［22］QU H，DENG M，WANG H，et al．Plasma CTRP-3 concentrations in Chinese patients with obesity and type II diabetes negatively correlate with insulin resistance［J］．J Clin Lipidol，2015，9（3）：289-294．DOI：10.1016/j.jacl.2015.03.006.
［23］DENG W Q，LI C Y，ZHANG Y P，et al．Serum C1q/TNF-related protein-3（CTRP3）levels are decreased in obesity and hypertension and are negatively correlated with parameters of insulin resistance［J］．Diabetol Metab Syndr，2015，7：33．DOI：10.1186/s13098-015-0029-0.
［24］FREITAS LIMA L C，BRAGA V A，FRAN?A-SILVA M S，et al．
Adipokines，diabetes and atherosclerosis：an inflammatory association［J］．Front Physiol，2015，6：304．DOI：10.3389/fphys.2015.00304.
［25］HU T Y，LI L M，PAN Y Z.CTRP3 inhibits high glucose-induced human glomerular mesangial cell dysfunction［J］．J Cell Biochem，2019，120（4）：5729-5736．DOI：10.1002/jcb.27859.
［26］LI X，JIANG L，YANG M，et al．CTRP3 improves the insulin sensitivity of 3T3-L1 adipocytes by inhibiting inflammation and ameliorating insulin signalling transduction［J］．Endokrynol Pol，2014，65（4）：252-258．DOI：10.5603/EP.2014.0034.
［27］WONG G W，KRAWCZYK S A，KITIDIS-MITROKOSTAS C，et al．Molecular，biochemical and functional characterizations of C1q/TNF family members：adipose-tissue-selective expression patterns，regulation by PPAR-Gamma agonist，cysteine-mediated oligomerizations，combinatorial associations and metabolic functions［J］．Biochem J，2008，416（2）：161-177．DOI：10.1042/BJ20081240.

[1]	LI Hao, LI Peijin, LIU Tingting, CUI Yiyuan, LI Sicong, LIU Lixing, FENG Li, Working Group on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment Guidelines for Cancer Pain. Guidelines on the Diagnosis and Treatment of Cancer Pain by Integrated Traditional Chinese and Western Medicine [J]. Chinese General Practice, 2025, 28(30): 3729-3740.
[2]	LU Donglei, YANG Fengying, FENG Zhanpeng, CAO Liquan, TAN Sijie. Conccurent Training Can Improve the Physical Health in Diabesity Individuals: a Meta-analysis [J]. Chinese General Practice, 2025, 28(27): 3410-3421.
[3]	ZHANG Yunuo, LI Ruibin, WANG Wei. Correlation Analysis of Serum Nesfatin-1 and Ghrelin Levels with Glycolipid Metabolism and Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2025, 28(26): 3264-3270.
[4]	ZHANG Ruimin, DONG Zheyi, LI Shuang, WANG Qian, CHEN Xiangmei. Traditional Chinese Medicine Factors Associated with Diabetic Nephropathy Diagnosed by Renal Biopsy [J]. Chinese General Practice, 2025, 28(26): 3307-3313.
[5]	ZHI Congcong, LI Xue, CHENG Yicheng, WANG Xiaolong, ZHENG Lihua. Guidelines for Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Hemorrhoids (2025 Edition) [J]. Chinese General Practice, 2025, 28(26): 3217-3228.
[6]	PAN Qi, REN Jingjing, MA Fanghui, HU Mengjie. Survey of General Practitioners' Cognition and Needs for AI Assisted Diagnosis and Treatment Systems [J]. Chinese General Practice, 2025, 28(25): 3127-3136.
[7]	YANG Chen, CHEN Tong, ZHANG Lifang, ZHANG Hongxu, LI Pengfei, ZHANG Xuejuan. Prognostic Impact of Dapagliflozin in Elderly Breast Cancer Survivors with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes [J]. Chinese General Practice, 2025, 28(24): 3053-3058.
[8]	WANG Rupeng, NAN Jing, HU Yiran, YANG Shenghua, JIN Zening. Predictive Value of the Triglyceride-Glucose Body Mass Index for Slow Flow/No-reflow Phenomenon in Patients with Type 2 Diabetes Mellitus and Acute Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention [J]. Chinese General Practice, 2025, 28(24): 2985-2992.
[9]	LIU Yueying, WANG Xueli, LIU Yuqiu, WEI Limin. Correlation of Fasting C-peptide to Diabetes Duration Ration and Type 2 Diabetes Mellitus Combined with Metabolism-related Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2852-2860.
[10]	WANG Peng, QIU Lixia, XU Shanshan, ZHANG Yang, ZHANG Jing, DU Xiaofei. Advances in the Co-management of Metabolism Dysfunction-associated Fatty Liver Disease and Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2025, 28(23): 2846-2851.
[11]	BAI Xue, CHEN Qianqian, LI Jie. Innovative Practices in Chronic Disease Management: a New Model for Generalist-Specialist Combination Management of Diabetes and Metabolic Dysfunction-associated Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2841-2845.
[12]	ADILI Tuersun, CHENG Gang. Meta-analysis of the Efficacy and Safety of Finerenone in the Treatment of Type 2 Diabetic Nephropathy [J]. Chinese General Practice, 2025, 28(21): 2686-2691.
[13]	Chinese Geriatrics Society, General Practice Branch of Zhejiang Medical Association, the Expert Collaboration Group on Medically Unspecified Disease in General Practice. Expert Consensus on the Diagnosis, Treatment, and Management of Emaciation (2025) [J]. Chinese General Practice, 2025, 28(21): 2577-2594.
[14]	LIU Hongya, YU Dehua. Construction and Practice of Clinical Diagnosis and Treatment Technology Combining General Practice and Specialist in Shanghai Community [J]. Chinese General Practice, 2025, 28(19): 2390-2397.
[15]	BIAN Ying, YIN Gang, ZHANG Zixun, TAO Hongbing. The Mechanism of Information Construction Enabling High-quality Development of Compact County-level Medical Consortium [J]. Chinese General Practice, 2025, 28(19): 2426-2432.